Tue, Jan 27, 2015, 5:02 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

ImmunoGen, Inc. Message Board

  • gappertrade gappertrade Feb 25, 2013 8:44 AM Flag

    Price target raised to $21.00 from $17.00 by Jefferies, what is it that you idiot sellers don't understand

    What is it that you moronic pre market sellers just don't seem to grasp in your small brains.

    Sentiment: Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • UPDATE: Jefferies Reiterates Buy Rating, Raises PT on ImmunoGen on Kadcyla Approval
      10:35a ET February 25, 2013 (Benzinga) In a report published Monday, Jefferies reiterated its Buy rating on ImmunoGen (NASDAQ: IMGN), and raised its price target from $17.00 to $21.00.

      Jefferies noted, “IMGN and partner Roche announced that Kadcyla (T-DM1) has been approved and priced at $9,800 per month. Kadcyla pricing is 33% higher than we had expected, and as a result, we are raising our IMGN PT from $17 to $21.”

    • I have to say, I was not a big fan of Thomas when he was against ARNA, but he was right the first time ARNA was rejected, then later he came around on them, long story short, I am warming up to him as an analyst, he's actually pretty good and I rarely say that. Maybe IMGN will make another run at $15 today.

      Just be glad you don't own AFFY today...a reminder the risk of biotech is substantial. I owned it from about $5-6 and sold at $13-15 and watched it go into the $20's. Had been thinking it was becoming a good value again lately, but was afraid of the falling knife chart pattern.

6.43-0.04(-0.62%)Jan 27 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.